Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03661866

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Atopic Dermatitis Alopecia Alopecia Areata Bacterial Infections Bacterial Infections and Mycoses Chronic Disease Chronic Spontaneous Urticaria Chronic Urticaria Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Disease Attributes Genetic Diseases, Inborn Hair Diseases Hidradenitis Hidradenitis Suppurativa Hypersensitivity Hypersensitivity, Immediate Hypopigmentation Hypotrichosis Immune System Diseases Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pigmentation Disorders Psoriasis Skin Diseases Skin Diseases, Bacterial Skin Diseases, Eczematous Skin Diseases, Genetic Skin Diseases, Infectious Skin Diseases, Papulosquamous Skin Diseases, Vascular Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases Urticaria Vitiligo

Sex eligibility

All sexes

Study type

Observational

Primary location

Skin Centre for Dermatology, Peterborough, Ontario, Canada

Loading trial locations.

About this study

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
  • 2. Participant has plans for future visits at the site for continued management of IMISC.

Exclusion criteria

  • 1. Inability to provide written informed consent/assent.
  • 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Treatment and study plan

Primary outcomes

  1. Characterize IMISC Treatment Regimens in Clinical Practice

    Time frame: 25 Years

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

  2. Evaluate Patient Outcomes in Clinical Practice

    Time frame: 25 Years

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

  3. Evaluate Adverse Events of IMISC and treatment in Clinical Practice

    Time frame: 25 Years

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Secondary outcomes

  1. Evaluate the relationship between IMISC and comorbid medical conditions

    Time frame: 25 Years

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

  2. Evaluate Patient Reported Outcome (PRO) measures

    Time frame: 25 Years

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

  3. Evaluate outcomes related to Patient Support Programs (PSPs)

    Time frame: 25 Years

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

Sponsors and collaborators

Lead sponsor

Target PharmaSolutions, Inc.

Industry

Registry information

Official study title

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

Acronym: TARGET-DERM

Important dates

Study start
2018
Primary completion
2050
Study completion
2050
First posted
Sep 7, 2018
Registry last updated
Mar 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.